|
|
|
|
LEADER |
04297nam a2200841Ia 4500 |
001 |
10.1186-s40545-020-00292-6 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 20523211 (ISSN)
|
245 |
1 |
0 |
|a Patterns of infections and antimicrobial drugs’ prescribing among pregnant women in Saudi Arabia: a cross sectional study
|
260 |
|
0 |
|b BioMed Central Ltd
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1186/s40545-020-00292-6
|
520 |
3 |
|
|a Background: Antimicrobial agents are among the most commonly prescribed drugs in pregnancy due to the increased susceptibility to infections during pregnancy. Antimicrobials can contribute to different maternal complications. Therefore, it is important to study their patterns in prescription and utilization. The data regarding this issue is scarce in Saudi Arabia. Therefore, the aim of this study is to generate data on the antimicrobial agents that are most commonly prescribed during pregnancy as well as their indications and safety. Methods: This is a retrospective study focusing on pregnant women with a known antimicrobial use at Johns Hopkins Aramco Healthcare (JHAH). The sample included 344 pregnant women with a total of 688 antimicrobial agents prescribed. Data was collected on the proportion of pregnant women who received antimicrobial agents and on the drug safety during pregnancy using the risk categorization system of the U.S. Food and Drug Administration (FDA). Results: The results showed that urinary tract infections (UTIs) were the most reported (59%) infectious diseases. Around 48% of pregnant women received antimicrobial medications at some point during pregnancy. The top two antimicrobial agents based on prescription frequency were B-lactams (44.6%) and azole anti-fungals (30%). The prescribed drugs in the study were found to be from classes B, C and D under the FDA risk classification system. Conclusion: The study revealed a high proportion of antimicrobials prescribed during pregnancy that might pose risks to mothers and their fetuses. Future multicenter studies are warranted to evaluate the rational prescription of antimicrobial medications during pregnancy. © 2021, The Author(s).
|
650 |
0 |
4 |
|a adolescent
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a aminoglycoside
|
650 |
0 |
4 |
|a antibiotic resistance
|
650 |
0 |
4 |
|a Antibiotics
|
650 |
0 |
4 |
|a antiinfective agent
|
650 |
0 |
4 |
|a antimalarial agent
|
650 |
0 |
4 |
|a Antimicrobial drugs
|
650 |
0 |
4 |
|a Antimicrobial resistance
|
650 |
0 |
4 |
|a antimicrobial stewardship
|
650 |
0 |
4 |
|a Antimicrobial stewardship programs
|
650 |
0 |
4 |
|a antivirus agent
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a beta lactam
|
650 |
0 |
4 |
|a cross-sectional study
|
650 |
0 |
4 |
|a disease predisposition
|
650 |
0 |
4 |
|a dopamine receptor stimulating agent
|
650 |
0 |
4 |
|a drug indication
|
650 |
0 |
4 |
|a drug safety
|
650 |
0 |
4 |
|a Drug utilization pattern
|
650 |
0 |
4 |
|a drug utilization review
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a first trimester pregnancy
|
650 |
0 |
4 |
|a gestational age
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a infection
|
650 |
0 |
4 |
|a Infections
|
650 |
0 |
4 |
|a macrolide
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a medical record review
|
650 |
0 |
4 |
|a mycosis
|
650 |
0 |
4 |
|a observational study
|
650 |
0 |
4 |
|a pregnancy
|
650 |
0 |
4 |
|a Pregnancy
|
650 |
0 |
4 |
|a pregnancy outcome
|
650 |
0 |
4 |
|a pregnant woman
|
650 |
0 |
4 |
|a prescription
|
650 |
0 |
4 |
|a pyrrole derivative
|
650 |
0 |
4 |
|a quinoline derived antiinfective agent
|
650 |
0 |
4 |
|a retrospective study
|
650 |
0 |
4 |
|a risk assessment
|
650 |
0 |
4 |
|a risk factor
|
650 |
0 |
4 |
|a Saudi Arabia
|
650 |
0 |
4 |
|a Saudi Arabia
|
650 |
0 |
4 |
|a tetracycline
|
650 |
0 |
4 |
|a third trimester pregnancy
|
650 |
0 |
4 |
|a time to treatment
|
650 |
0 |
4 |
|a treatment duration
|
650 |
0 |
4 |
|a urinary tract infection
|
700 |
1 |
|
|a Al Ghamdi, M.S.
|e author
|
700 |
1 |
|
|a Alboghdadly, A.
|e author
|
700 |
1 |
|
|a Al-Ghamdi, F.H.
|e author
|
700 |
1 |
|
|a AlLehaibi, L.H.
|e author
|
700 |
1 |
|
|a Alotaibi, B.S.
|e author
|
700 |
1 |
|
|a Alsulaiman, D.
|e author
|
700 |
1 |
|
|a AlSuwaidan, H.N.
|e author
|
700 |
1 |
|
|a Babar, Z.-U.-D.
|e author
|
700 |
1 |
|
|a Baraka, M.A.
|e author
|
700 |
1 |
|
|a Homoud, A.H.
|e author
|
700 |
1 |
|
|a Islam, M.A.
|e author
|
773 |
|
|
|t Journal of Pharmaceutical Policy and Practice
|